Search

everythinglearnresearchcommunity

for

Search:↓

The health of the sentinel lymph node is the best indicator of survival for patients with thick skin cancer.

Shorter PSADT after prostate surgery is linked to higher risk of death.

FUE and FUT hair transplants have similar success rates, with FUE slightly better.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Chemotherapy may help with survival in children with medulloblastoma, but more research is needed.

Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.

FUT-MD hair transplants have higher follicle survival rates than FUE transplants.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

Sorafenib after liver surgery may increase survival for some liver cancer patients.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Palliative chemotherapy is cost-effective for advanced gastric and colorectal cancer but not clearly for pancreatic-biliary cancer.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.